Navivumab
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2[1].
Product Specifications
CAS Number
1443004-16-7
Product Name Alternative
CT-P23
UNSPSC
12352203
Target
Influenza Virus
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/navivumab.html
Purity
99.10
Solubility
10 mM in DMSO
Smiles
[Navivumab]
Molecular Weight
(146.6 kDa)
References & Citations
[1]Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis. 2018 Dec;31 (6) :527-534.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
E40KMP1791 20 µg
Recombinant Human ACE2 Protein with hFc tag, Fc His Tag
Sign In for Pricing
View Details 037458-ML750 100 µL
KIR2DS1, ID (KIR2DS1, CD158H, Killer cell immunoglobulin-like receptor 2DS1, CD158 antigen-like family member H, MHC class I NK cell receptor Eb6 ActI, CD158h) (MaxLight 750) discontinued
Sign In for Pricing
View Details bsm-41268M-BF680-01 20 µL
SARS-CoV-2 (2019-nCoV) Nucleocapsid (1E8) Monoclonal Antibody, AbBy Fluor™ 680 Conjugated
Sign In for Pricing
View Details